Ray Furey
Executive Vice President, General Counsel, and Corporate Secretary
Replay available
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q1 2026 earnings conference call, held 2026-05-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Raul Rodriguez
President and Chief Executive Officer
Dave Santos
Chief Commercial Officer
Lisa Royker
Chief Medical Officer
Dean Shorno
Chief Financial Officer
Joel Panginis
Analyst, H.C. Wainwright & Co.
Amin An
Analyst, Jefferies (on behalf of Farzeen)
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rigel Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.318 Greetings and welcome to Rigel Pharmaceutical's financial conference call for the first 00:00:04.318 -- 00:00:06.541 quarter, 2026. 00:00:06.541 -- 00:00:09.766 At this time, all participants are in a listen-only mode. 00:00:09.766 -- 00:00:12.630 A brief question and answer session will follow the formal presentation. 00:00:12.630 -- 00:00:16.736 If anyone should require operator assistance during the conference, please press star 00:00:16.736 -- 00:00:21.715 zero on your telephone keypad. As a reminder, this conference is being recorded. 00:00:21.715 -- 00:00:27.222 It is now my pleasure to introduce our speaker, Ray Furey, Rigel's Executive Vice President, 00:00:27.222 -- 00:00:30.305 General Counsel, and Corporate Secretary. Thank you. 00:00:30.305 -- 00:00:33.767 Mr. Furey, you may begin. 00:00:33.990 -- 00:00:39.736 Welcome to our first quarter of 2026 financial results business update conference call. 00:00:39.736 -- 00:00:46.062 The financial press release for the first quarter of 2026 was issued a short while ago. 00:00:49.036 -- 00:00:53.961 section of our investor relations site on Rytle.com. 00:00:54.847 -- 00:00:59.235 As a reminder, during today's call, we may make forward-looking statements regarding 00:00:59.235 -- 00:01:04.445 our financial outlook and our plans and timing for regulatory product development. 00:01:04.445 -- 00:01:09.194 These statements are subject to risks and uncertainties that may cause actual results 00:01:09.194 -- 00:01:11.547 to differ from those forecasted. 00:01:11.547 -- 00:01:16.713 A description of these risks can be found in our most recent annual report, Form 10-K, 00:01:16.713 -- 00:01:20.475 for the year ended December 31st, 2025, 00:01:20.758 -- 00:01:26.065 on file with the SEC, a...